Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
批准号:
10661539
负责人:
Alexander Egbe
金额:
$56.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-08-01 至 2026-07-31
关键词:
AccelerationAdultAerobicAgeAmericanArrhythmiaBiological MarkersBlood TestsCardiovascular systemCessation of lifeChronicClinicalClinical TrialsComplicationDataDeteriorationDevelopmentDiagnosticDiseaseEarly treatmentEchocardiographyEnrollmentEventExercise TestFutureGoalsHealth Care CostsHeartHeart AtriumHypertensionImageImpairmentInferior vena cava structureKnowledgeLaboratoriesLifeLife ExpectancyLinkMissionMorbidity - disease rateOperative Surgical ProceduresOutcomeOxygen ConsumptionPathogenesisPatientsPersonsPopulationPostoperative PeriodPreventionPrevention therapyProcessPublic HealthPulmonary Valve InsufficiencyRecurrenceReportingResearchRiskRisk FactorsSymptomsTechniquesTestingTetralogy of FallotTherapeutic InterventionTimeTroponinUncertaintyUnited States National Institutes of HealthVentricular Arrhythmiaarmburden of illnesscardiac magnetic resonance imagingcohortdisabilityeffective therapyevidence baseextracellularfollow-uphemodynamicsimprovedimproved outcomeindexinginnovationmortalitynovel therapeuticsprematurepressurepreventpro-brain natriuretic peptide (1-76)pulmonary valve replacementrepairedright ventricular failuresymptomatic improvementtreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Right heart failure (RHF) is the leading cause of mortality in people with repaired tetralogy of Fallot (TOF), and
the sequence of events leading to this suboptimal outcome begins with pulmonary regurgitation (PR) and right
heart (RH) remodeling. Arrhythmias and impaired aerobic capacity are the most common presentations prior to
the onset of RHF, but performing pulmonary valve replacement (PVR) after the onset of these symptoms is not
associated with improved outcomes. Recent data show that elevated right atrial pressure (RA hypertension),
as estimated by echocardiographic assessment of inferior vena cava (IVC) size and collapsibility (IVC hemo-
dynamics), precedes the onset of arrhythmias and impaired aerobic capacity in TOF patients, and it is associ-
ated with accelerated RH remodeling, symptomatic deterioration and mortality in this population. However, the
mechanism linking RA hypertension, RH remodeling and symptomatic deterioration, and the extent to which
performing PVR prior to the onset of RA hypertension improves clinical outcomes are unknown. The long-term
goal is to prevent premature cardiovascular deaths in TOF patients by modifying the risk factors for mortality.
The overall objective is to delineate the pathophysiologic mechanism linking RA hypertension, RH remodeling
and onset of symptoms such as arrhythmias and impaired aerobic capacity, since symptomatic status is a risk
factor for mortality in the TOF population. Our central hypothesis is that RA hypertension leads to accelerated
RH remodeling and onset of symptoms (arrhythmias and impaired aerobic capacity), and that performing PVR
prior to onset of RA hypertension is associated with RH reverse remodeling and improvement of symptoms.
This hypothesis will be tested by pursuing two specific aims: (1) Determine the mechanism linking RA hyper-
tension (assessed by IVC hemodynamics), RH remodeling and onset of symptoms (arrhythmias and impaired
aerobic capacity) in TOF patients with moderate-severe PR; (2) Determine the extent to which performing PVR
prior to the onset of RA hypertension is associated with RH reverse remodeling (improvement of imaging and
biomarker indices of RH remodeling) and improvement of symptoms (less arrhythmias and improved aerobic
capacity). Under the first aim, 150 asymptomatic subjects (75 in each arm) will undergo imaging, laboratory
blood tests, exercise test, and patient reported quality of assessment at baseline, 12 months and 24 months.
Under the second aim, 120 subjects (60 in each arm) undergoing PVR for clinical indications will be enrolled to
undergo multi-domain assessments at baseline (prior to PVR), 12 months and 24 months similar to the first
aim. This proposal is innovative because it will delineate the mechanisms responsible for symptomatic deterio-
ration, and the impact of PVR on these mechanisms. The results will be significant because it will set the stage
for future clinical trials to test the survival benefits of PVR performed at different stages of disease pathogene-
sis, and development of novel therapies for the prevention and early treatment of RHF.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Prevalence and risk of progressive aortic aneurysm and dissection in adults with conotruncal anomalies.
患有圆锥干异常的成人进行性主动脉瘤和夹层的患病率和风险。
DOI:
10.1093/ehjci/jeab273
发表时间:
2022
期刊:
European heart journal. Cardiovascular Imaging
影响因子:
--
作者:
[Egbe,AlexanderC, Miranda,WilliamR, Bonnichsen,CrystalR, Jain,CCharles, Crestanello,JuanA, Francois,Christopher, Katta,RenukaR, Iftikhar,Momina, Goda,AhmedY, Andi,Kartik, Gandhi,Sangeetha, Connolly,HeidiM]
通讯作者:
Connolly,HeidiM
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
-
批准号:10734120
-
项目类别:
-
资助金额:$69.53万
-
财政年份:2023
-
负责人:Alexander Egbe
-
依托单位:
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
-
批准号:10458752
-
项目类别:
-
资助金额:$57.29万
-
财政年份:2021
-
负责人:Alexander Egbe
-
依托单位:
Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology
-
批准号:10542724
-
项目类别:
-
资助金额:$64.0万
-
财政年份:2021
-
负责人:Alexander Egbe
-
依托单位:
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
-
批准号:10268589
-
项目类别:
-
资助金额:$59.22万
-
财政年份:2021
-
负责人:Alexander Egbe
-
依托单位:
Ventricular and Pulmonary Vascular Reserve after the Fontan Operation
-
批准号:10133126
-
项目类别:
-
资助金额:$17.33万
-
财政年份:2018
-
负责人:Alexander Egbe
-
依托单位:
海外基金